Clinical TrialsSNDX reported positive data from both the AUGMENT-101 and BEAT-AML studies for first-in-class menin inhibitor, Revuforj in r/r NPM1, NUP98r and newly diagnosed NPM1/KMT2Ar AML patients.
Market PenetrationThe company expects over 50% market penetration in the primary market for Revuforj in the first year.
Sales PerformanceRevuforj outperformed in its first full quarter with $20M in sales, overshadowing concerns about GAAP EPS.